ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0401

Direct to Patient Screening of Psoriatic Arthritis: Clinical Findings and Outcomes of Patient-Driven Rheumatology Referrals

Megan Meier1 and Jessica Walsh2, 1University of Utah, North Salt Lake, UT, 2University of Utah, Salt Lake City, UT

Meeting: ACR Convergence 2022

Keywords: Psoriatic arthritis, Surveys

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 12, 2022

Title: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Diagnostic delays are common with psoriatic arthritis (PsA), and screening surveys for identifying at-risk patients are infrequently used in busy clinical practices. We previously demonstrated that patients with psoriasis were more frequently evaluated by a rheumatologist if they screened positively on a home screening survey and then contacted study staff directly for a rheumatology appointment. This method bypassed an initial screening by their primary doctors. In this sub-analysis, we sought to characterize the patient findings during the initial rheumatologic evaluation. Our goal was to determine whether their referral to rheumatology was clinically appropriate.

Methods: Within the University of Utah and VA Medical Center healthcare systems in Salt Lake City, patients with an International Classification of Diseases (ICD) code for psoriasis but not PsA in the electronic health record (EHR) were identified. The Psoriasis Epidemiology Screening Tool Survey1 was disseminated electronically and via postal mail beginning 9/18/20 (index date). Patients that screened positively were instructed to contact study staff for a rheumatology appointment. Patient characteristics, clinical findings and diagnostic outcomes were extracted from the EHR beginning 2/2/22. A rheumatology referral was deemed appropriate if the patient had: (1) a history of confirmed or probable psoriasis; and (2) no previous encounters with a rheumatologist within the last 6 years. They also had to have: (3) a diagnosis of PsA; OR (4) symptoms, examination findings or test results that warranted an additional workup or a rheumatology follow-up.

Results: The population included 1,413 patients, of whom 27 were seen by a rheumatologist. 66.6% were male with a mean age of 61.5. 14.8% had a previous encounter with a rheumatologist that was nondiagnostic for PsA. 59.2% had a verified history of psoriasis by a dermatologist or primary care provider. The most common clinical finding was enthesitis (33.3%) of the Achilles, plantar fascia insertions or epicondyles (Table 1). PsA diagnosis occurred in 4.7%. An additional 6.7% were diagnosed with possible PsA or another inflammatory joint disease (Figure 1). The rheumatology referral was deemed appropriate in 63%.

Conclusion: With patient-driven PsA screening and rheumatology referrals, over half of the referrals were deemed appropriate. The rate of misdiagnosed psoriasis was high due to inaccurate ICD code data. While the rate of PsA diagnosis was low, a dedicated evaluation by a rheumatologist in this at-risk population can provide reassurance and valuable patient education. There is also a highly beneficial impact for those who were diagnosed with PsA. Patient engagement may improve with future study cohorts (n≈24,000 patients), as the impacts of the COVID-19 pandemic decline and adjustments are made to engagement strategies.

1Ibrahim GH, et al. Clin Exp Rheumatol. 2009; 27:469-74.

Supporting image 1

*Fulfilled Calin Criteria for inflammatory back pain. †The total number of studies ordered. ‡ Erosions, sacroiliac changes or active inflammation seen on peripheral or axial radiographs, MRI or ultrasound.

Supporting image 2


Disclosures: M. Meier, None; J. Walsh, AbbVie, Amgen, Lilly, Novartis, Pfizer, UCB, Celgene, Janssen, Merck.

To cite this abstract in AMA style:

Meier M, Walsh J. Direct to Patient Screening of Psoriatic Arthritis: Clinical Findings and Outcomes of Patient-Driven Rheumatology Referrals [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/direct-to-patient-screening-of-psoriatic-arthritis-clinical-findings-and-outcomes-of-patient-driven-rheumatology-referrals/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/direct-to-patient-screening-of-psoriatic-arthritis-clinical-findings-and-outcomes-of-patient-driven-rheumatology-referrals/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology